131 related articles for article (PubMed ID: 38538560)
1. Study of prognostic splicing factors in cancer using machine learning approaches.
Yang M; Liu J; Kim P; Zhou X
Hum Mol Genet; 2024 Jun; 33(13):1131-1141. PubMed ID: 38538560
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis reveals the prognostic value and functions of splicing factors implicated in hepatocellular carcinoma.
Wang Y; Yang F; Shang J; He H; Yang Q
Sci Rep; 2021 Jul; 11(1):15175. PubMed ID: 34312475
[TBL] [Abstract][Full Text] [Related]
3. PCBP1 regulates the transcription and alternative splicing of metastasis‑related genes and pathways in hepatocellular carcinoma.
Huang S; Luo K; Jiang L; Zhang XD; Lv YH; Li RF
Sci Rep; 2021 Dec; 11(1):23356. PubMed ID: 34857818
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
5. Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma.
Zhao YJ; Wu LY; Pang JS; Liao W; Chen YJ; He Y; Yang H
Bioengineered; 2021 Dec; 12(1):3978-3992. PubMed ID: 34288818
[TBL] [Abstract][Full Text] [Related]
6. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
Xing L; Zhang X; Tong D
DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
[TBL] [Abstract][Full Text] [Related]
7. Systematic profiling of a novel prognostic alternative splicing signature in hepatocellular carcinoma.
Zhang D; Duan Y; Wang Z; Lin J
Oncol Rep; 2019 Dec; 42(6):2450-2472. PubMed ID: 31578577
[TBL] [Abstract][Full Text] [Related]
8. Multilayered control of splicing regulatory networks by DAP3 leads to widespread alternative splicing changes in cancer.
Han J; An O; Ren X; Song Y; Tang SJ; Shen H; Ke X; Ng VHE; Tay DJT; Tan HQ; Kappei D; Yang H; Chen L
Nat Commun; 2022 Apr; 13(1):1793. PubMed ID: 35379802
[TBL] [Abstract][Full Text] [Related]
9. Development of a nomogram for prognostic prediction of lower-grade glioma based on alternative splicing signatures.
Wang Y; Wang Z; Zhao B; Chen W; Wang Y; Ma W
Cancer Med; 2020 Dec; 9(24):9266-9281. PubMed ID: 33047900
[TBL] [Abstract][Full Text] [Related]
10. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
[TBL] [Abstract][Full Text] [Related]
11. Prognostic index of aberrant mRNA splicing profiling acts as a predictive indicator for hepatocellular carcinoma based on TCGA SpliceSeq data.
Wu HY; Peng ZG; He RQ; Luo B; Ma J; Hu XH; Dang YW; Chen G; Pan SL
Int J Oncol; 2019 Aug; 55(2):425-438. PubMed ID: 31268164
[TBL] [Abstract][Full Text] [Related]
12. MAPP unravels frequent co-regulation of splicing and polyadenylation by RNA-binding proteins and their dysregulation in cancer.
Bak M; van Nimwegen E; Kouzel IU; Gur T; Schmidt R; Zavolan M; Gruber AJ
Nat Commun; 2024 May; 15(1):4110. PubMed ID: 38750024
[TBL] [Abstract][Full Text] [Related]
13. The combinatorial control of alternative splicing in C. elegans.
Tan JH; Fraser AG
PLoS Genet; 2017 Nov; 13(11):e1007033. PubMed ID: 29121637
[TBL] [Abstract][Full Text] [Related]
14. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma.
Wan Q; Sang X; Jin L; Wang Z
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099
[TBL] [Abstract][Full Text] [Related]
15. TF-RBP-AS Triplet Analysis Reveals the Mechanisms of Aberrant Alternative Splicing Events in Kidney Cancer: Implications for Their Possible Clinical Use as Prognostic and Therapeutic Biomarkers.
He M; Hu F
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445498
[TBL] [Abstract][Full Text] [Related]
16. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel RNA Binding Proteins Influencing Circular RNA Expression in Hepatocellular Carcinoma.
Razpotnik R; Nassib P; Kunej T; Rozman D; Režen T
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299096
[TBL] [Abstract][Full Text] [Related]
18. Identification of prognostic and metastasis-related alternative splicing signatures in hepatocellular carcinoma.
Huang R; Yan G; Sun H; Zhang J; Song D; Kong R; Yan P; Hu P; Xie A; Wang S; Zhuang J; Yin H; Meng T; Huang Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32627826
[TBL] [Abstract][Full Text] [Related]
19. SUVA: splicing site usage variation analysis from RNA-seq data reveals highly conserved complex splicing biomarkers in liver cancer.
Cheng C; Liu L; Bao Y; Yi J; Quan W; Xue Y; Sun L; Zhang Y
RNA Biol; 2021 Oct; 18(sup1):157-171. PubMed ID: 34152934
[TBL] [Abstract][Full Text] [Related]
20. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
Vadlamudi Y; Dey DK; Kang SC
Curr Cancer Drug Targets; 2020; 20(9):654-665. PubMed ID: 32564755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
